Clinical trials: Stage I Cervical Cancer
Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
The purpose of the Phase I part of this research study is to determine the safest and most effective dose of Abraxane when given in combination with carboplatin and Erbitux during radiation therapy for head and neck cancer.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma, Undifferentiated Carcinoma, Adenosquamous Cell Carcinoma
- Trial name
- NCT00570674
- Testing
- Abraxane, Erbitux, Carboplatin
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer.
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Vaginal Adenocarcinoma
- Trial name
- NCT02595879
- Testing
- Biospecimen Collection, Brachytherapy, Cisplatin
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell of Head and Neck
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
- Trial name
- NCT02101034
- Testing
- Cetuximab, PD 0332991
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed.
- Trial name
- NCT00453336
- Testing
- Porfimer Sodium, Photodynamic Therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Miami
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This pilot randomized phase I/II trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with cetuximab and to see how well it works in treating patients with recurrent or metastatic head and…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01816984
- Testing
- PI3K inhibitor BKM120, cetuximab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Vaginal Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT02280811
- Testing
- Fludarabine, Cyclophosphamide, E6 TCR
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Resectable Head and Neck Squamous Cell Carcinoma
Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers
The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate…
- Trial name
- HART-HN (NCT05120947)
- Testing
- 42 Gy Radiation Therapy, 39 Gy Radiation Therapy, 32.5 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Solid Tumors
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
The study evaluates safety of adavosertib in monotherapy, and in combination with 5-Fluorouracil (5-FU) alone or with 5-FU/cis-diamminedichloroplatinum (CDDP) in Japanese participants with solid tumor.
- Trial name
- NCT01047007
- Testing
- adavosertib 20 mg, 5-FU 1000 mg/m^2/day, CDDP
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Total Laryngectomy
Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis
The purpose of this study is to investigate the performance of a new voice prosthesis in comparison with the Provox2 and the Provox ActiValve voice prosthesis in 15 laryngectomized patients.
- Trial name
- NCT00743262
- Testing
- Provox voice prosthesis
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Atos Medical AB
Breast Cancer, Lung Cancer
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
- Conditions
- Breast Cancer, Lung Cancer, Colon Cancer, Pancreatic Cancer
- Trial name
- NCT01012362
- Testing
- Pazopanib, Ixabepilone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Renal Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the…
- Conditions
- Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma
- Trial name
- NCT02111850
- Testing
- Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment.
- Conditions
- Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma, Stage I Thyroid Gland Papillary Carcinoma
- Trial name
- NCT01811212
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
In phase I of the trial, the investigators aim to explore the safety and feasibility of abemaciclib in combination with nivolumab in patients with recurrent/metatstatic head and neck squamous cell carcinoma (RM-HNSCC).
- Trial name
- NCT03655444
- Testing
- Abemaciclib, Nivolumab, Tumor biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Head and Neck Cancer
Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00530088
- Testing
- porfimer sodium, Photdynamic Therapy (PDT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
This phase I trial studies the side effects and best dose of berzosertib (M6620) when given together with cisplatin and radiation therapy in treating patients with head and neck squamous cell carcinoma that has spread from where…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02567422
- Testing
- Berzosertib, Cisplatin, Computed Tomography
- Where
- 19 sites in United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Cervical Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma
- Trial name
- NCT02153905
- Testing
- Aldesleukin, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
This phase II trial studies the effect of chemoradiation and pembrolizumab followed by pembrolizumab and lenvatinib before surgery in treating patients with esophageal or esophageal/gastroesophageal junction cancer that has not…
- Conditions
- Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04929392
- Testing
- Carboplatin, Endoscopic Biopsy, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer, Gastric Cancer
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033657
- Testing
- cisplatin, irinotecan hydrochloride, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eastern Cooperative Oncology Group